Long-term effects of zonisamide in adult patients with intellectual disability.

摘要: OBJECTIVE This study aimed to evaluate the tolerability and efficacy of zonisamide (ZNS) in adult patients with drug-resistant epilepsy intellectual disability (ID) at our centre. PATIENTS AND METHODS By conducting a monocentric, open-label observational based on standardized seizure records we retrospectively assessed 87 (39 female, mean age 40.6 ± 13.6, range 18-75 years) ID epilepsy. Evaluation, including calculation retention rate, was performed for intervals 3-6, 9-12 21-24 months after ZNS initiation. The Clinical Global Impressions Scale-Improvement (CGI-I) used detect qualitative changes severity clinical status. Via regression analysis generalized estimating equations approach, examined body weight impact patient also considering associations other characteristics. RESULTS rate 24 months 60%. 28% discontinued therapy due increasing frequency, lack or adverse events (AEs). Sedation (38%), language impairment (19%), challenging behaviour (10%), mild rash (10%) dizziness were commonest AEs. responder 40%, eight (9%) became free. We found CGI-I be dose-dependent. Regarding weight, observed no difference between continuing withdrawing responders non-responders. Though, identified older as significant risk factor loss. CONCLUSIONS Zonisamide may provide safe efficient therapeutic option However, status should carefully monitored, especially elderly patients.